Skip To Main Content
Le contenu de ce site web est exclusivement réservé aux professionnels de santé en Belgique et au Luxembourg.
Campus
  • Aires thérapeutiques
  • Ressources
Campus
  • Aires thérapeutiques
  • Ressources
View Full Results

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques

The observational ORION study

Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan.

Explorer

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Explorer

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Explorer

Le pouvoir de réduire le chaos lié au VRS

Explorer

When to Initiate Basal Insulin?

Practical Guidance based on the 2022 ADA/EASD Guidelines.

Explorer

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Explorer

Cardiovascular diseases (CVDs) are the leading cause of death globally

Explorer

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Explorer

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Explorer

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Explorer

Signs and symptoms of aTTP

Know the signs and symptoms of acquired TTP (aTTP).

Explorer

What is TTP? A rare, life-threatening medical emergency

Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.

Explorer